{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008457","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.577189+00:00","generated_at":"2026-06-18T00:49:06.192527+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ORIC Pharma reports Q4 2022 cash of $228.2M; Pfizer invests $25M; Phase 1b data expected H2 2023","bullets":["Cash and investments $228.2M at Dec 31, 2022; runway into first half of 2025.","Pfizer purchased 5.4M shares at $4.65/share for $25M equity investment; collaboration on ORIC-533 + elranatamab combo.","R&D expenses $16.3M in Q4 2022 vs $16.7M in Q4 2021; full-year R&D $61.7M vs $56.9M.","Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in second half of 2023.","Selected a PLK4 inhibitor development candidate; Jeff Settleman (Pfizer) joined Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008457","json":"https://secwatch.observer/filing/0000950170-23-008457.json","markdown":"https://secwatch.observer/filing/0000950170-23-008457.md","text":"https://secwatch.observer/filing/0000950170-23-008457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/0000950170-23-008457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/oric-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:49:06.192527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be9a49d52365a0814a0c3ad37f085ce9ba38aa7d","claim":"Oric Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/0000950170-23-008457-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}